- About Us
- Career Center
- Nano-Social Network
- Nano Consulting
- My Account
Emergency Filtration Products, Inc. (EFP) (PINKSHEETS: EMFP) today issued the following update:
Parallel shelf life and efficacy tests are being conducted on the biocidal silver nanoparticle coated filter media that is used in EFP's NanoMask. The first series of tests is being conducted on samples stored at 60 degrees C (140 degrees F) and the second set of testing is being conducted on samples stored at 45 degrees C (113 F). The tests are designed to simulate a minimum of one year of aging in order to demonstrate that the NanoMask filter could be inventoried for an extended period and still be effective in eradicating certain pathogens.
The higher temperature test, which is partially complete, is likely to be more difficult in attaining the highest possible kill rate on various pathogens. When exposed to extreme temperatures, the silver nanoparticles applied to the NanoMask filter media are expected to lose some activity and hence capability to eradicate virus and bacteria.
Independent laboratory tests on the 60 degree C aged samples demonstrate that the silver nanoparticle formulation coated filter media killed 99.75% of the avian influenza strain H9N2. Tests performed on samples aged just 48 hours resulted in a 99.99% kill rate against avian influenza. In addition, tests against Staphylococcus aureus demonstrated kill rates ranging from 99.30% to 99.50% for S. aureus. The kill rate for Streptococcus pneumoniae was 99.99%.
The results of the second test should be known in late March 2008. The second test is being conducted at a lower temperature. It should have less impact on the activity of the silver nanoparticle component and thus achieve desired results. The results from this test are expected to generate results necessary to re-file a 510k submission with the FDA.
About Emergency Filtration Products
EFP was formed to develop a preeminent filtration technology that would serve to ensure the safety of rescuers by virtually eliminating risk of cross-contamination during CPR. Our goal was to elevate the confidence of caregivers to the point where fear of exposure to contagious disease would not cause even a moment's hesitation.
Safe Harbor Statement
This release may contain statements that are forward-looking. Such statements are made based upon current expectations that are subject to risk and uncertainty. EFP and ANI do not undertake to update forward-looking statements in this news release to reflect actual results of and changes in assumptions or changes in other factors affecting such forward-looking information. The actual future plans and results of the companies could differ significantly from such forward-looking statements.
For more information, please click here
800-477-7570 or 212-344-6464
PAN Consultants Ltd.
Copyright © MarketwireIf you have a comment, please Contact us.
Issuers of news releases, not 7th Wave, Inc. or Nanotechnology Now, are solely responsible for the accuracy of the content.
|Related News Press|
News and information